

# Mathematical Statistics II

STA2212H S LEC9101

Week 6

February 11 2025

## School phone bans alone do not improve grades or wellbeing, says UK study

Researchers say bans need to be part of wider strategy to tackle negative impact of mobile use on children



The negative effects of phone use were not different between schools that banned phones and

# School phone policies and their association with mental wellbeing, phone use, and social media use (SMART Schools): a cross-sectional observational study

Victoria A. Goodyear,<sup>a,b,\*</sup> Amie Randhawa,<sup>a,b</sup> Pérymane Adab,<sup>c</sup> Hareth Al-Janabi,<sup>b,c</sup> Sally Fenton,<sup>a,d</sup> Kirsty Jones,<sup>e</sup> Maria Michail,<sup>b,f</sup> Breanna Morrison,<sup>c</sup> Paul Patterson,<sup>b,g</sup> Jonathan Quinlan,<sup>a,d</sup> Alice Sitch,<sup>c,d,h</sup> Rebecca Twardochleb,<sup>a,b</sup> Matthew Wade,<sup>h,i</sup> and Miranda Pallan<sup>c</sup>



<sup>a</sup>School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK

<sup>b</sup>Institute for Mental Health, University of Birmingham, Birmingham, UK

<sup>c</sup>Department of Applied Health Sciences, University of Birmingham, Birmingham, UK

<sup>d</sup>National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, UK

<sup>e</sup>Services for Education, Birmingham, UK

<sup>f</sup>School of Psychology, University of Birmingham, Birmingham, UK

<sup>g</sup>Forward Thinking Birmingham, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK

<sup>h</sup>ukactive, ukactive Research Institute, London, UK

<sup>i</sup>Advanced Wellbeing Research Centre, College of Health, Wellbeing and Life Sciences, Sheffield Hallam University, Sheffield, UK

1. Project: Choice of papers
2. HW6 due Feb 26
3. Recap Feb 4 **decision theory, efficiency**
4. Theory of interval estimation
5. Approximations to the posterior
6. HW5, Statistics in the News

**Department Seminar Thursday February 13 11.00 – 12.00**

Hydro Building, Room 9014

Robust nonparametrics and spatial data

Pratheepa Jeganathan, McMaster University

MS 7.1

MS 7.2



The poster is for a seminar by Pratheepa Jeganathan. It features a portrait of her on the right. The text on the left includes the University of Toronto logo, her name, her title as Assistant Professor in the Department of Mathematics and Statistics, and the seminar details: 'UPCOMING SPEAKER', '13 Feb', '11:00 am room 9014', and 'STATISTICS COLLOQUIUM'. The title of the talk is 'A Robust Nonparametric Framework for Detecting Repeated Spatial Clusters'. A detailed abstract follows, discussing spatial clustering, repeated patterns, and the use of Maximum Mean Discrepancy (MMD) and block permutation for robustness evaluation.

Statistical Sciences  
UNIVERSITY OF TORONTO

**PRATHEEPA  
JEGANATHAN**

Assistant Professor in the Department of  
Mathematics and Statistics, McMaster  
University

**UPCOMING  
SPEAKER**

**13  
Feb**  
11:00 am  
room 9014

**STATISTICS  
COLLOQUIUM**

A Robust Nonparametric Framework for Detecting Repeated  
Spatial Clusters

Ensuring spatial contiguity in spatial clustering is often critical, as nearby observations exhibit dependencies. Equally important, however, is identifying repeated spatial clusters that may not be spatially contiguous. Traditional clustering techniques, such as constrained hierarchical clustering, constrained partitioning, and density-based clustering, are commonly used to ensure spatial contiguity. Despite their strengths, these methods often fail to detect repeated spatial patterns consistently, particularly under varying degrees of spatial dependence. This talk introduces a post-clustering framework to enhance constrained clustering techniques by identifying repeated spatial clusters. Specifically, constrained clustering methods often overestimate the number of clusters when repeated patterns are present. Our framework incorporates a nonparametric test based on Maximum Mean Discrepancy (MMD) and block permutation to assess the distributions of multivariate attributes within the clusters identified by constrained methods. I will discuss the performance of the proposed framework through a simulation study, evaluating its robustness across varying levels of spatial dependence, cluster shapes, the number of multivariate attributes, and spatial locations.

- Loss function squared-error, absolute error, ...
- Risk function expected loss
- Admissible point estimators not inadmissible
- Bayes risk average over  $\pi(\theta)$
- Bayes estimator minimize Bayes risk

- Bayes risk

$$R_B(\hat{\theta}) = \int R_{\theta}(\hat{\theta})\pi(\theta)d\theta$$

- Optimal Bayes estimators minimize the Bayes risk
- Equivalent to minimizing posterior loss:  $\int L\{\hat{\theta}(\mathbf{x}), \theta\}\pi(\theta | \mathbf{x})d\theta$

- Example: absolute-error loss

$$\min_{\hat{\theta}} \int |\hat{\theta} - \theta|\pi(\theta | \mathbf{x})d\theta$$

- solution  $\hat{\theta}(\mathbf{x}) = \text{median } \pi(\theta | \mathbf{x})$

posterior median

- Suppose  $\hat{\theta}$  is a Bayes estimator **and is unique**
- Suppose we have another estimator  $\tilde{\theta}$  with a smaller frequentist risk function:

$$R_{\theta}(\tilde{\theta}) \leq R_{\theta}(\hat{\theta})$$

- The Bayes risk of  $\tilde{\theta}$  is  $R_B(\tilde{\theta}) = \int$

- Suppose  $\hat{\theta}$  is a Bayes estimator **and is unique**
- Suppose we have another estimator  $\tilde{\theta}$  with a smaller frequentist risk function:

$$R_{\theta}(\tilde{\theta}) \leq R_{\theta}(\hat{\theta})$$

- The Bayes risk of  $\tilde{\theta}$  is  $R_B(\tilde{\theta}) = \int$
- instead of finding estimator to minimize the **weighted** average of the risk function we could

$$\min \max R_{\theta}(\hat{\theta})$$

Definition §6.2  
admissible

- such estimators are called **minimax**
- Bayes estimators with constant risk are minimax

- finding the 'best' point estimator  $\hat{\theta}$
- best = smallest expected loss
- no asymptotic theory involved
- can find these using a Bayesian argument
- but the justification is not Bayesian
- another non-asymptotic approach to 'best' estimators: UMVU

MS 6.3

- $X_1, \dots, X_n$  i.i.d.  $f(x; \theta), \theta \in \mathbb{R}$
- a **100(1 -  $\alpha$ )% confidence interval** for  $\theta$  is a random interval  $[L(\mathbf{X}), U(\mathbf{X})]$  with

continuous

- similarly, upper and lower  $(1 - \alpha)$ -confidence bounds:

$$\text{pr}\{\theta \geq L(\mathbf{X})\} = 1 - \alpha; \quad \text{pr}\{\theta \leq U(\mathbf{X})\} = 1 - \alpha$$

- $X_1, \dots, X_n$  i.i.d.  $f(x; \theta), \theta \in \mathbb{R}$
- a **100(1 -  $\alpha$ )% confidence interval** for  $\theta$  is a random interval  $[L(\mathbf{X}), U(\mathbf{X})]$  with

continuous

- similarly, upper and lower  $(1 - \alpha)$ -confidence bounds:

$$\text{pr}\{\theta \geq L(\mathbf{X})\} = 1 - \alpha; \quad \text{pr}\{\theta \leq U(\mathbf{X})\} = 1 - \alpha$$

- **exact** limits if we have exact distribution of  $\mathbf{X}$
- approximate limits if  $\text{pr}_\theta\{L(\mathbf{X}) \leq \theta \leq U(\mathbf{X})\} \approx 1 - \alpha$

- Example:  $X_1, \dots, X_n$  i.i.d.  $N(\mu, 1)$

- Example:  $X_1, \dots, X_n$  i.i.d.  $N(\mu, 1)$
- Example  $X_1, \dots, X_n$  i.i.d.  $U(0, \theta)$

$$\text{pr}(a \leq \frac{X_{(n)}}{\theta} \leq b)$$

- Example:  $X_1, \dots, X_n$  i.i.d.  $N(\mu, 1)$
- Example  $X_1, \dots, X_n$  i.i.d.  $U(0, \theta)$
- Example  $X_1, \dots, X_n$  i.i.d.  $N(\mu, \sigma^2)$

$$\text{pr}(a \leq \frac{X_{(n)}}{\theta} \leq b)$$

pivotal quantities

- Example:  $X \sim \text{Binom}(n, \theta)$ ,  $\hat{\theta} \sim N(\theta, \theta(1 - \theta)/n)$

MS Ex.7.6

$$\text{pr}_{\theta} \left[ -1.96 \leq \frac{\sqrt{n}(\hat{\theta} - \theta)}{\{\theta(1 - \theta)\}^{1/2}} \leq 1.96 \right] \approx 0.95$$

- Example:  $X \sim \text{Binom}(n, \theta)$ ,  $\hat{\theta} \sim N(\theta, \theta(1 - \theta)/n)$

MS Ex.7.6

$$\text{pr}_{\theta} \left[ -1.96 \leq \frac{\sqrt{n}(\hat{\theta} - \theta)}{\{\theta(1 - \theta)\}^{1/2}} \leq 1.96 \right] \approx 0.95$$

$$\text{pr}_{\theta} \left[ -1.96 \leq \frac{\sqrt{n}(\hat{\theta} - \theta)}{\{\hat{\theta}(1 - \hat{\theta})\}^{1/2}} \leq 1.96 \right] \approx 0.95$$

- Example:  $X \sim \text{Binom}(n, \theta)$ ,  $\hat{\theta} \sim N(\theta, \theta(1 - \theta)/n)$

MS Ex.7.6

$$\text{pr}_{\theta} \left[ -1.96 \leq \frac{\sqrt{n}(\hat{\theta} - \theta)}{\{\theta(1 - \theta)\}^{1/2}} \leq 1.96 \right] \approx 0.95$$

$$\text{pr}_{\theta} \left[ -1.96 \leq \frac{\sqrt{n}(\hat{\theta} - \theta)}{\{\hat{\theta}(1 - \hat{\theta})\}^{1/2}} \leq 1.96 \right] \approx 0.95$$

- $\hat{\theta}_n$  maximum likelihood estimate
- approximate 95% confidence interval

$$\hat{\theta} \sim N[0, \{nl(\theta)\}^{-1}]$$


AoS Thm 6.16

- $X_1, \dots, X_n$  i.i.d.  $\text{Exp}(\lambda)$       $f(x_i; \lambda) =$

- $\hat{\lambda} =$

- $g(\lambda) = \log \lambda$

**n= 10**



```

simexp <- function(n = 10, nsim=30, set.seed = 2024){
  ci1 <- ci2 <- matrix(0, nrow=nsim, ncol=2)
  for(i in 1:nsim){
    x <- rexp(n,1)
    hatlam <- 1/mean(x)
    ci1[i,] <- c(hatlam - 1.96*hatlam/sqrt(n),
                 hatlam + 1.96*hatlam/sqrt(n))
    ci2[i,] <- c(hatlam*exp(-1.96/sqrt(n)),
                 hatlam*exp(1.96/sqrt(n)))}



  plot(0:3,0:3, type="n", xlab = "", ylab = "",
        main=paste(c("n="),n))
  for(i in 1:nsim){
    lines(x=ci1[i,],
          y = c((i-1)/10, (i-1)/10),
          col="blue")
    lines(x=ci2[i,],
          y = c(.05+(i-1)/10, .05+(i-1)/10),
          col="red")}
  abline(v=1)
}

```

- upper and lower bounds
- equi-tailed posterior intervals
- highest posterior density

$$\theta \in \mathbb{R}$$

$$\theta \in \mathbb{R}^p, p \geq 1$$



[Link](#) to Guardian

Pfizer-BioNTech vaccine trial:

vaccine: 22000 subjects, 8 cases

placebo: 22000 subjects, 162 cases

$8/162 = 5\% \implies 95\%$  efficacy

data released November 18 2020 [link](#)

published December 31 2020 in NEJM [link](#)

Behind the numbers: what does it mean if a Covid vaccine has '90% efficacy'?

*David Spiegelhalter and Anthony Masters*

Confusion surrounds the vaccines' effectiveness. The leading Cambridge professor clarifies the data behind the trials



▲ People rest in Salisbury Cathedral, England, after receiving the Pfizer/BioNTech vaccine. Photograph: Neil Hall/EPA

Editor's Note: This article was published on December 10, 2020, at NEJM.org.

ORIGINAL ARTICLE

## Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack, M.D., Stephen J. Thomas, M.D., Nicholas Kitchin, M.D., Judith Absalon, M.D., Alejandra Gurtman, M.D., Stephen Lockhart, D.M., John L. Perez, M.D., Gonzalo Pérez Marc, M.D., Edson D. Moreira, M.D., Cristiano Zerbini, M.D., Ruth Bailey, B.Sc., Kena A. Swanson, Ph.D., [et al.](#), for the C4591001 Clinical Trial Group\*



Article   Figures/Media

Metrics

December 31, 2020

N Engl J Med 2020; 383:2603-2615

DOI: 10.1056/NEJMoa2034577

[Chinese Translation](#) [中文翻译](#)



[13 References](#)   [263 Citing Articles](#)   [Letters](#)

Results: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: **21,720** with BNT162b2 and **21,728** with placebo. There were **8** cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and **162** cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (**95% credible interval, 90.3 to 97.6**).

**Table 2.** Vaccine Efficacy against Covid-19 at Least 7 days after the Second Dose.\*

| Efficacy End Point                                                                                                     | BNT162b2     |                        | Placebo      |                        | Vaccine Efficacy, %<br>(95% Credible Interval)‡ | Posterior Probability<br>(Vaccine Efficacy >30%)§ |
|------------------------------------------------------------------------------------------------------------------------|--------------|------------------------|--------------|------------------------|-------------------------------------------------|---------------------------------------------------|
|                                                                                                                        | No. of Cases | Surveillance Time (n)† | No. of Cases | Surveillance Time (n)† |                                                 |                                                   |
|                                                                                                                        | (N=18,198)   |                        | (N=18,325)   |                        |                                                 |                                                   |
| Covid-19 occurrence at least 7 days after the second dose in participants without evidence of infection                | 8            | 2.214 (17,411)         | 162          | 2.222 (17,511)         | 95.0 (90.3–97.6)                                | >0.9999                                           |
|                                                                                                                        | (N=19,965)   |                        | (N=20,172)   |                        |                                                 |                                                   |
| Covid-19 occurrence at least 7 days after the second dose in participants with and those without evidence of infection | 9            | 2.332 (18,559)         | 169          | 2.345 (18,708)         | 94.6 (89.9–97.3)                                | >0.9999                                           |

\* The total population without baseline infection was 36,523; total population including those with and those without prior evidence of infection was 40,137.

† The surveillance time is the total time in 1000 person-years for the given end point across all participants within each group at risk for the end point. The time period for Covid-19 case accrual is from 7 days after the second dose to the end of the surveillance period.

‡ The credible interval for vaccine efficacy was calculated with the use of a beta-binomial model with prior beta (0.700102, 1) adjusted for the surveillance time.

§ Posterior probability was calculated with the use of a beta-binomial model with prior beta (0.700102, 1) adjusted for the surveillance time.

- vaccine group 18000 participants; 8 cases
- placebo group 18000 participants; 162 cases
- $0.05 = 8/162 \rightarrow 95\%$  efficacy
- model

$$X_1 \sim \text{Poisson}(\lambda\psi), \quad X_2 \sim \text{Poisson}(\lambda) \quad X_1 \mid S = X_1 + X_2 \sim \text{Binom}(S, \psi/(1 + \psi))$$

- prior  $\text{Beta}(a, b) \rightarrow$  posterior  $\text{Beta}(x_1 + a, s - x_1 + b)$

# Credible intervals

- vaccine group 18000 participants; 8 cases
- placebo group 18000 participants; 162 cases
- $0.05 = 8/162 \rightarrow 95\%$  efficacy
- model

$$X_1 \sim \text{Poisson}(\lambda\psi), \quad X_2 \sim \text{Poisson}(\lambda) \quad X_1 \mid S = X_1 + X_2 \sim \text{Binom}(S, \psi/(1 + \psi))$$

- prior  $\text{Beta}(a, b) \rightarrow$  posterior  $\text{Beta}(x_1 + a, s - x_1 + b)$

- `qbeta(c(0.025,0.975), shape1 = 8.7, shape2 = 163)`
- `> [1] 0.02319 0.08799`
- `1- .Last.value/(1-.Last.value)`
- `> [1] 0.97625 0.90352`

$$VE = 1 - \psi$$

# Approximate normality of posterior

- $X_1, \dots, X_n \sim f(x^n \mid \theta), \quad \theta \sim \pi(\theta), \quad \pi(\theta \mid x^n) = \frac{f(x^n \mid \theta)}{f(x^n)} \quad x^n = (x_1, \dots, x_n)$
- $\pi(\theta \mid x^n) \approx N\{\hat{\theta}, j^{-1}(\hat{\theta})\}; \quad \pi(\theta \mid x^n) \approx N\{\tilde{\theta}, \tilde{j}(\tilde{\theta})\}$

# Approximate normality of posterior

- $X_1, \dots, X_n \sim f(x^n | \theta), \quad \theta \sim \pi(\theta), \quad \pi(\theta | x^n) = \frac{f(x^n | \theta)}{f(x^n)} \quad x^n = (x_1, \dots, x_n)$

- $\pi(\theta | x^n) \approx N\{\hat{\theta}, j^{-1}(\hat{\theta})\}; \quad \pi(\theta | x^n) \approx N\{\tilde{\theta}, \tilde{j}(\tilde{\theta})\}$

- careful statement

Berger, 1985; Ch.4

- For any  $a, b \in \mathbb{R}, a < b$
- let  $a_n = \hat{\theta}_n + aj^{-1/2}(\hat{\theta}_n), b_n = \hat{\theta}_n + bj^{-1/2}(\hat{\theta}_n)$
- $\hat{\theta}_n$  is the solution of  $\ell'(\theta; x^n) = 0$ , assumed unique, and  $j(\theta) = -\ell''(\theta; x^n)$

Then

$$\int_{a_n}^{b_n} \pi(\theta | x^n) d\theta \longrightarrow \Phi(b) - \Phi(a), \quad n \rightarrow \infty.$$

need  $\pi(\theta) > 0, \pi'(\theta)$  continuous

# Approximate normality of posterior

- $X_1, \dots, X_n \sim f(x^n \mid \theta), \quad \theta \sim \pi(\theta), \quad \pi(\theta \mid x^n) = \frac{f(x^n \mid \theta)}{f(x^n)} \quad x^n = (x_1, \dots, x_n)$
- $\pi(\theta \mid x^n) \approx N\{\hat{\theta}, j^{-1}(\hat{\theta})\}; \quad \pi(\theta \mid x^n) \approx N\{\tilde{\theta}, \tilde{j}(\tilde{\theta})\}$
- approximate posterior probability intervals

- multiparameter model  $f(\mathbf{X}; \boldsymbol{\theta})$

$$\text{pr}_{\boldsymbol{\theta}}\{\boldsymbol{\theta} \in R(\mathbf{X})\} \geq 1 - \alpha,$$

for all  $\boldsymbol{\theta}$ , with equality for some  $\boldsymbol{\theta}$

- pivotal method:

$$1 - \alpha = \text{pr}_{\boldsymbol{\theta}}\{a \leq g(\mathbf{X}; \boldsymbol{\theta}) \leq b\} = \text{pr}_{\boldsymbol{\theta}}\{\boldsymbol{\theta} \in R(\mathbf{X})\}$$

- Example:  $\mathbf{X}_1, \dots, \mathbf{X}_n$  i.i.d.  $N_p(\boldsymbol{\mu}, \Sigma)$
- exact pivot

MS Ex.7.8

$$g(\mathbf{X}; \boldsymbol{\mu}) = \frac{n(n-p)}{p(n-1)} (\hat{\boldsymbol{\mu}} - \boldsymbol{\mu})^T \hat{\Sigma}^{-1} (\hat{\boldsymbol{\mu}} - \boldsymbol{\mu})$$

- multiparameter model  $f(\mathbf{X}; \boldsymbol{\theta})$

$$\text{pr}_{\boldsymbol{\theta}}\{\boldsymbol{\theta} \in R(\mathbf{X})\} \geq 1 - \alpha,$$

for all  $\boldsymbol{\theta}$ , with equality for some  $\boldsymbol{\theta}$

- pivotal method:

$$1 - \alpha = \text{pr}_{\boldsymbol{\theta}}\{a \leq g(\mathbf{X}; \boldsymbol{\theta}) \leq b\} = \text{pr}_{\boldsymbol{\theta}}\{\boldsymbol{\theta} \in R(\mathbf{X})\}$$

- Example:  $\mathbf{X}_1, \dots, \mathbf{X}_n$  i.i.d.  $N_p(\boldsymbol{\mu}, \Sigma)$

MS Ex.7.8

- exact pivot

$$g(\mathbf{X}; \boldsymbol{\mu}) = \frac{n(n-p)}{p(n-1)} (\hat{\boldsymbol{\mu}} - \boldsymbol{\mu})^T \hat{\Sigma}^{-1} (\hat{\boldsymbol{\mu}} - \boldsymbol{\mu})$$

•

$$R(\mathbf{X}) = \{\boldsymbol{\mu} : \frac{n(n-p)}{p(n-1)} (\hat{\boldsymbol{\mu}} - \boldsymbol{\mu})^T \hat{\Sigma}^{-1} (\hat{\boldsymbol{\mu}} - \boldsymbol{\mu}) \leq f_{1-\alpha}\}$$

$F_{p, n-p}$


- HPD region C for  $\theta$ :

$$(1) \quad \int_C \pi(\theta \mid \mathbf{x}) = 1 - \alpha$$

$$(2) \quad \pi(\theta \mid \mathbf{x}) \geq \pi(\theta^* \mid \mathbf{x})$$

582

11 · Bayesian Models



**Figure 11.2** Posterior densities of  $(\mu, \sigma^2)$  of normal model for maize data. Left: contours of the normalized log joint posterior density. Right: marginal posterior density for  $\mu$ , showing 95% HPD credible set, which is the set of values of  $\mu$  whose values of the posterior density  $\pi(\mu \mid y)$  lie above the dashed line. The shaded region has area 0.05.

# Approximate confidence regions

- maximum likelihood estimator is approximately normal

- 

$$\hat{\theta} \sim N\{\theta, I_n^{-1}(\hat{\theta})\} \implies (\hat{\theta} - \theta)^T I_n(\hat{\theta})(\hat{\theta} - \theta) \sim \chi_k^2$$

- 

$$1 - \alpha \approx \text{pr}_{\theta}\{\theta \in R(\hat{\theta})\}$$

- 

$$R(\hat{\theta}) = \{\theta : (\hat{\theta} - \theta)^T I_n(\hat{\theta})(\hat{\theta} - \theta) \leq \chi_{k,1-\alpha}^2\}$$

# Approximate confidence regions

- maximum likelihood estimator is approximately normal

- 

$$\hat{\theta} \sim N\{\theta, I_n^{-1}(\hat{\theta})\} \implies (\hat{\theta} - \theta)^T I_n(\hat{\theta})(\hat{\theta} - \theta) \sim \chi_k^2$$

- 

$$1 - \alpha \approx \text{pr}_{\theta}\{\theta \in R(\hat{\theta})\}$$

- 

$$R(\hat{\theta}) = \{\theta : (\hat{\theta} - \theta)^T I_n(\hat{\theta})(\hat{\theta} - \theta) \leq \chi_{k,1-\alpha}^2\}$$

- $k = 1$ :

$$\hat{\theta} \pm z_{1-\alpha/2} \widehat{se}(\hat{\theta})$$

AoS Thm 6.16

# Likelihood ratio based approximate confidence regions

- $X_1, \dots, X_n \sim f(\mathbf{x}; \theta)$
- $L(\theta; \mathbf{x}) = f(\mathbf{x}; \theta), \quad \ell(\theta) = \log L(\theta; \mathbf{x})$

- 

$$w(\theta) = 2\{\ell(\hat{\theta}) - \ell(\theta)\} \xrightarrow{d} \chi_p^2, \quad n \rightarrow \infty$$

# Likelihood ratio based approximate confidence regions

- $X_1, \dots, X_n \sim f(\mathbf{x}; \theta)$
- $L(\theta; \mathbf{x}) = f(\mathbf{x}; \theta), \quad \ell(\theta) = \log L(\theta; \mathbf{x})$

- 

$$w(\theta) = 2\{\ell(\hat{\theta}) - \ell(\theta)\} \xrightarrow{d} \chi_p^2, \quad n \rightarrow \infty$$

- approximation:

$$w(\theta) \sim \chi_p^2$$

- approximate confidence region

$$\{\theta : w(\theta) \leq \chi_{p,1-\alpha}^2\}$$

- model  $Y \sim f(y; \psi, \lambda)$ ,  $\psi \in \mathbb{R}, \lambda \in \mathbb{R}^{d-1}$ ,  $\theta = (\psi, \lambda)$   $y = (y_1, \dots, y_n)$
- log-likelihood function  $\ell(\psi, \lambda; y) = \log f(y; \psi, \lambda) = \sum \log f(y_i; \psi, \lambda)$  if independent
- profile log-likelihood function  $\ell_p(\psi) = \ell(\psi, \hat{\lambda}_\psi)$  maximize over  $\lambda$
- maximum likelihood estimate  $j_p(\psi) = -\ell_p''(\psi)$

$$\hat{\psi} \sim N\{\psi, j_p^{-1/2}(\psi)\} \implies 1 - \alpha \text{ CI} \approx \hat{\psi} \pm z_{1-\alpha/2} \hat{j}_p^{1/2}$$

- likelihood ratio test

$$2\{\ell_p(\hat{\psi}) - \ell_p(\psi)\} \sim \chi_1^2 \implies 1 - \alpha \text{ CI} \approx \{\psi : 2\{\ell_p(\hat{\psi}) - \ell_p(\psi)\} \leq \chi_{1,1-\alpha}^2\}$$


- model  $Y \sim f(y; \psi, \lambda)$ ,  $\psi \in \mathbb{R}, \lambda \in \mathbb{R}^{d-1}$ ,  $\theta = (\psi, \lambda)$   $y = (y_1, \dots, y_n)$
- log-likelihood function  $\ell(\psi, \lambda; y) = \log f(y; \psi, \lambda) = \sum \log f(y_i; \psi, \lambda)$  if independent
- profile log-likelihood function  $\ell_p(\psi) = \ell(\psi, \hat{\lambda}_\psi)$  maximize over  $\lambda$

- maximum likelihood estimate

$$\hat{\psi} \sim N\{\psi, j_p^{-1/2}(\psi)\} \implies 1 - \alpha \text{ CI} \approx \hat{\psi} \pm$$

- likelihood ratio test

$$2\{\ell_p(\hat{\psi}) - \ell_p(\psi)\} \sim \chi_1^2 \implies 1 - \alpha \text{ CI} \approx \{\psi : 2\{\ell_p(\hat{\psi}) - \ell_p(\psi)\} \leq \chi_{1-\alpha}^2\}$$



- recall  $X_1, \dots, X_n, i.i.d. F(\cdot)$

- empirical cdf

$$\hat{F}_n(t) = \frac{1}{n} \sum_{i=1}^n 1\{X_{(i)} \leq t\}$$

- properties:

$$\mathbb{E}\{\hat{F}_n(t)\} = F(t), \quad \text{var}\{\hat{F}_n(t)\} = \frac{1}{n} F(t)\{1 - F(t)\}$$

any fixed  $t$

- pointwise approximate confidence limits  $\hat{F}_n(t) \pm z_{1-\alpha/2} [\hat{F}_n(t)\{1 - \hat{F}_n(t)\}]^{1/2}$

- recall  $X_1, \dots, X_n, i.i.d. F(\cdot)$
- empirical cdf

$$\hat{F}_n(t) = \frac{1}{n} \sum_{i=1}^n 1\{X_{(i)} \leq t\}$$

- properties:

$$\mathbb{E}\{\hat{F}_n(t)\} = F(t), \quad \text{var}\{\hat{F}_n(t)\} = \frac{1}{n} F(t)\{1 - F(t)\}$$

any fixed  $t$

- pointwise approximate confidence limits  $\hat{F}_n(t) \pm z_{1-\alpha/2} [\hat{F}_n(t)\{1 - \hat{F}_n(t)\}]^{1/2}$
- simultaneous confidence band :  $\text{pr}\{L(t) \leq F(t) \leq U(t) \text{ for all } t\} \geq 1 - \alpha$ :

$$L(t) = \max\{\hat{F}_n(t) - \epsilon_n, 0\}, \quad U(t) = \min\{\hat{F}_n(t) + \epsilon_n, 1\}, \quad \epsilon_n = \left\{ \frac{1}{2n} \log \left( \frac{2}{\alpha} \right) \right\}^{1/2}$$

98 7. Estimating the CDF and Statistical Functionals




FIGURE 7.1. Nerve data. Each vertical line represents one data point. The solid line is the empirical distribution function. The lines above and below the middle line are a 95 percent confidence band.

**7.2 Example (Nerve Data).** Cox and Lewis (1966) reported 799 waiting times between successive pulses along a nerve fiber. Figure 7.1 shows the empirical CDF  $\hat{F}_n$ . The data points are shown as small vertical lines at the bottom of the plot. Suppose we want to estimate the fraction of waiting times between .4 and .6 seconds. The estimate is  $\hat{F}_n(.6) - \hat{F}_n(.4) = .93 - .84 = .09$ . ■

## Example: Bootstrap confidence intervals

```
> alpha = 0.05
>
> # Normal-based CI
> c(phat - qnorm(1-alpha/2)*sd(bs_est),
+   phat + qnorm(1-alpha/2)*sd(bs_est))
[1] 0.05709686 0.44290314
>
> # Percentile CI
> c(quantile(bs_est, alpha/2),
+   quantile(bs_est, 1-alpha/2))
2.5% 97.5%
0.10  0.45
0.10  0.45
```

Calculate in R

$$\Rightarrow n = z_0 = \begin{cases} 5 \text{ successes} \\ 15 \text{ failures} \end{cases}$$

## Example: Bootstrap confidence intervals

